Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX – Get Free Report) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 483 shares, a growth of ∞ from the August 15th total of 0 shares. Based on an average trading volume of 1,006 shares, the days-to-cover ratio is currently 0.5 days.
Insider Activity
In related news, CFO Lee Kalowski sold 3,972 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the sale, the chief financial officer directly owned 138,471 shares in the company, valued at $2,293,079.76. The trade was a 2.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Pope Morrison sold 9,845 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $163,033.20. Following the sale, the chief executive officer directly owned 343,259 shares of the company’s stock, valued at approximately $5,684,369.04. This represents a 2.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 16,615 shares of company stock worth $275,144.
Leverage Shares 2X Long FIX Daily ETF Price Performance
Shares of Leverage Shares 2X Long FIX Daily ETF stock opened at $11.87 on Wednesday. Leverage Shares 2X Long FIX Daily ETF has a 12-month low of $11.21 and a 12-month high of $14.30.
Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.
Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.
See Also
- Five stocks we like better than Leverage Shares 2X Long FIX Daily ETF
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Leverage Shares 2X Long FIX Daily ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leverage Shares 2X Long FIX Daily ETF and related companies with MarketBeat.com's FREE daily email newsletter.
